Recently, a combination of TIM-3 inhibitor TSR-022 and PD-1 inhibitor dostarlimab is conducted at the University of Pittsburgh in a clinical trial for Stage III or IV melanoma patients. This evidence concerns the gene HAVCR2 and melanoma.